文献速递临床免疫临床血液与体液分子诊断

正常碱性磷酸酶水平下抗线粒体抗体与PBC特异性抗核抗体对非典型原发性胆汁性胆管炎的评估价值

Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels.
PubMed 文献 · Clin Chem Lab Med · 2025-08-20

该研究回顾性纳入2016年1月至2024年7月南京市第二医院抗线粒体抗体(AMA)和/或PBC特异性抗核抗体(ANA)阳性且碱性磷酸酶(ALP)正常的患者,按抗体谱分三组比较PBC诊断率、临床表现、实验室结果和病理。结果显示53.3%(88/165)患者有胆管炎活动并诊断为PBC,三组PBC诊断率分别为82.1%(23/28)、48.4%(46/95)和45.2%(19/42)。多因素分析显示无肝病相关病因、基线血清IgM超过0.796倍正常上限与肝活检诊断PBC显著相关,三者联合AUC达0.84。

要点

  • AMA和/或PBC特异性ANA阳性且ALP正常者中超过50%诊断为PBC。
  • AMA/AMA-M2与gp210/sp100双阳性组PBC诊断率最高(82.1%)。
  • 基线IgM>0.796×ULN且无其他肝病病因时建议肝活检,联合AUC为0.84。

核心结论

  • AMA和/或PBC特异性ANA阳性且ALP正常的患者中超过50%存在PBC。
  • 建议对这类抗体阳性患者行肝活检,尤其当基线血清IgM超过0.796倍正常上限且无其他肝病相关病因时。

研究设计与样本

  • 回顾性研究,纳入2016年1月至2024年7月南京市第二医院AMA/PBC-ANAs阳性且ALP正常的患者共165例。
  • 按自身抗体谱分为三组:[AMA/AMA-M2]+[gp210/sp100]+组28例、[AMA/AMA-M2]+[gp210/sp100]-组95例、[AMA/AMA-M2]-[gp210/sp100]+组42例。
  • 比较各组PBC诊断率、临床症状、实验室结果和病理。

主要发现

  • 53.3%(88/165)的患者有胆管炎活动并诊断为PBC。
  • 三组PBC诊断率分别为82.1%(23/28)、48.4%(46/95)和45.2%(19/42)。
  • 多因素分析显示无肝病相关病因(p<0.001)和基线血清IgM超过0.796倍正常上限(p<0.001)与肝活检诊断PBC显著相关。
  • 非PBC患者主要病理损伤模式为轻微非特异性反应性改变(40.0%/28.6%/39.1%)、炎症(40.0%/24.5%/47.8%)和脂肪变(20%/20.4%/4.3%)。
  • 非PBC诊断包括病毒性肝炎、自身免疫性肝炎、脂肪肝病、血管性肝病、药物性肝损伤、先天性肝纤维化和卟啉病。

关键数值与推荐

  • 基线血清IgM超过0.796倍正常上限为与肝活检诊断PBC相关的指标。
  • 无肝病相关病因与肝活检诊断PBC显著相关(p<0.001)。
  • 上述指标联合诊断PBC的AUC为0.84。

临床怎么用

  • 对AMA和/或PBC特异性ANA阳性且ALP正常的患者应警惕PBC可能。
  • 当基线IgM超过0.796×ULN且无其他肝病病因时,建议行肝活检以明确诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The clinical implications of positive anti-mitochondrial antibodies (AMAs) and/or primary biliary cholangitis (PBC)-specific anti-nuclear antibodies (ANAs) in patients with normal alkaline phosphatase (ALP) remain uncertain. METHODS: Patients at The Second Hospital of Nanjing with positive AMAs/PBC-ANAs and normal ALP levels from January 2016 to July 2024 were categorized into three groups based on autoantibody profiles: [AMA/AMA-M2]+[gp210/sp100]+, [AMA/AMA-M2]+[gp210/sp100]-, and [AMA/AMA-M2]-[gp210/sp100]+. The study compared PBC diagnostic rates, clinical symptoms, laboratory results, and pathology across these groups. RESULTS: A total of 53.3 % (88/165) of the patients showed cholangitis activity diagnosed of PBC. The PBC diagnosis rate in the three groups was 82.1 % (23/28), 48.4 % (46/95), and 45.2 % (19/42) respectively. Multivariate analysis indicated a significant association between the absence of liver disease-related etiology (p<0.001), baseline serum immunoglobulin M (IgM) exceeding 0.796 times the upper limit of normal (ULN) (p<0.001), and the diagnosis of PBC as determined by liver biopsy. In the three groups of non-PBC patients, the major pathological injury patterns were minor nonspecific reactive changes (40.0 %/28.6 %/39.1 %), inflammation (40.0 %/24.5 %/47.8 %), and fatty changes (20 %/20.4 %/4.3 %). The diagnosis included viral hepatitis, autoimmune hepatitis, fatty liver disease, vascular liver disorders, drug-induced liver injury, congenital hepatic fibrosis, and porphyria. CONCLUSIONS: Over 50 % of patients with positive PBC-specific antibodies and normal ALP have PBC. Liver biopsy is recommended when AMAs and/or PBC-specific ANAs are positive, especially when baseline serum IgM exceeds 0.796 × ULN, and when other etiologies related to liver disease are absent. The area under the curve (AUC) for these three indicators reaches 0.84.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Li S, Zhang K, Liu H, et al. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels. Clin Chem Lab Med. 2025. PMID: 40829001. doi:10.1515/cclm-2025-0357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。